Abstract:Atherosclerosis and its associated cardiovascular diseases (CVDs) are serious threats to human health and have been reported to be associated with the gut microbiota. Recently, the role of berberine (BBR) in atherosclerosis and gut microbiota has begun to be appreciated. The purposes of this study were to observe the effects of high or low doses of BBR on atherosclerosis and gut microbiota modulation, and to explore their correlation in ApoE–/– mice fed a high-fat diet. A significant decrease in atherosclerotic lesions was observed after treatment with BBR, with the effect of the high dose being more obvious. Both BBR treatments significantly reduced total cholesterol, APOB100, and very low-density lipoprotein cholesterol levels but levels of high/low-density lipoprotein cholesterol and lipoprotein (a) were only reduced by high-dose BBR. Decreased pro-inflammatory cytokines tumor necrosis factor-alpha, interleukin (IL)-1β, IL-6 and increased anti-inflammatory IL-10 and adiponectin levels were observed in the high-dose BBR group, but no decrease in IL-6 or increase in IL-10 was evident using the low-dose of BBR. 16S rRNA sequencing showed that BBR significantly altered the community compositional structure of gut microbiota. Specifically, BBR enriched the abundance of Roseburia, Blautia, Allobaculum, Alistipes, and Turicibacter, and changed the abundance of Bilophila. These microbiota displayed good anti-inflammatory effects related to the production of short-chain fatty acids (SCFAs) and were related to glucolipid metabolism. Alistipes and Roseburia were significantly enriched in high-dose BBR group while Blautia and Allobaculum were more enriched in low-dose, and Turicibacter was enriched in both BBR doses. Metagenomic analysis further showed an elevated potential for lipid and glycan metabolism and synthesis of SCFAs, as well as reduced potential of TMAO production after BBR treatment. The findings demonstrate that both high and low-dose BBR can improve serum lipid and systemic inflammation levels, and alleviate atherosclerosis induced by high-fat diet in ApoE–/– mice. The effects are more pronounced for the high dose. This anti-atherosclerotic effect of BBR may be partly attributed to changes in composition and functions of gut microbiota which may be associated with anti-inflammatory and metabolism of glucose and lipid. Notably, gut microbiota alterations showed different sensitivity to BBR dose.

Berberine Inhibits Low Shear Stress-Induced Vascular Endothelial Inflammation Via Decreasing Phosphorylation of Akt and IRF3

Berberine Protects Human Umbilical Vein Endothelial Cells Against LPS-Induced Apoptosis by Blocking JNK-Mediated Signaling

Berberine inhibits free fatty acid and LPS-induced inflammation via modulating ER stress response in macrophages and hepatocytes

Berberine alleviates NLRP3 inflammasome induced endothelial junction dysfunction through Ca2+ signaling in inflammatory vascular injury

Berberine Protects against TNF-α-Induced Injury of Human Umbilical Vein Endothelial Cells via the AMPK/NF-κB/YY1 Signaling Pathway

Suppressive effects of berberine on atherosclerosis via downregulating visfatin expression and attenuating visfatin-induced endothelial dysfunction

Berberine Inhibition of Fibrogenesis in a Rat Model of Liver Fibrosis and in Hepatic Stellate Cells.

Berberine as a novel ACSL4 inhibitor to suppress endothelial ferroptosis and atherosclerosis

Activation Of Amp-Activated Protein Kinase Is Required For Berberine-Induced Reduction Of Atherosclerosis In Mice: The Role Of Uncoupling Protein 2

Berberine Alleviates Insulin Resistance and Inflammation via Inhibiting the LTB4–BLT1 Axis

Berberine Improves High-Fat Diet Induced Atherosclerosis and Hepatic Steatosis in Apoe-/-Mice by Down-Regulating PCSK9 via ERK1/2 Pathway

Inhibition of Angiotension II Type 1 Receptor Reduced Human Endothelial Inflammation Induced by Low Shear Stress

Berberine Improves Inflammatory Responses of Diabetes Mellitus in Zucker Diabetic Fatty Rats and Insulin-Resistant HepG2 Cells through the PPM1B Pathway

Berberine attenuates atherosclerotic lesions and hepatic steatosis in ApoE-/- mice by down-regulating PCSK9 via ERK1/2 pathway

Protective Effect of Berberine Against LPS-induced Endothelial Cell Injury Via the JNK Signaling Pathway and Autophagic Mechanisms

Berberine Hydrochloride Protects Cytokine-Induced Inflammation through Multiple Pathways

Berberine prevents progression from hepatic steatosis to steatohepatitis and fibrosis by reducing endoplasmic reticulum stress

Berberine attenuates inflammation and oxidative stress and modulates lymphocyte E‐NTPDase in acute hyperlipidemia

Berberine Inhibits Low Shear Stress-Induced Glycocalyx Degradation Via Modulating AMPK and P47phox/hyal2 Signal Pathway

Berberine alleviates ulcerative colitis by inhibiting inflammation through targeting IRGM1

Effect of Berberine on Atherosclerosis and Gut Microbiota Modulation and Their Correlation in High-Fat Diet-Fed ApoE−/− Mice